Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

Diabetes

Diabetic kidney disease: act now or pay later

Nature Reviews Nephrology volume 6, pages 134–136 (2010)Cite this article

Subjects

In 2003, the International Society of Nephrology and the International Diabetes Federation launched a campaign to highlight the global pandemic of type 2 diabetes and diabetic kidney disease. It aimed to alert governments, health organizations, health-care providers, doctors, and patients to the increasing health and socioeconomic problems associated with diabetic kidney disease and its sequelae, end-stage renal disease. Today, 7 years later, the same message is even more urgent.

World Kidney Day 2010, under the auspices of the International Society of Nephrology (ISN) and the International Federation of Kidney Foundations (IFKF), together with the International Diabetes Federation (IDF), provides a chance to underscore the importance of diabetic kidney disease, stress the lack of awareness of this condition at both public and governmental levels, and emphasize that its management involves prevention, recognition, and treatment of complications. Primary prevention of type 2 diabetes requires massive lifestyle changes in the developing and developed world, supported by strong governmental commitment to promote lifestyle and societal changes.

This is a preview of subscription content, access via your institution

Relevant articles

Open Access articles citing this article.

Access options

Rent or buy this article

Get just this article for as long as you need it

$39.95

Learn more

Prices may be subject to local taxes which are calculated during checkout

References

  1. Sicree, R., Shaw, J. & Zimmet, P. in Diabetes Atlas 3rd edn (ed. Gan, D.) 15–109 (International Diabetes Federation, 2006).

    Google Scholar 

  2. Retnakaran, R. et al. Risk factors for renal dysfunction in type 2 diabetes: UK Prospective Diabetes Study 74. Diabetes 55, 1832–1839 (2006).

    Article  CAS  Google Scholar 

  3. Parving, H. H. et al. Prevalence and risk factors for microalbuminuria in a referred cohort of type II diabetic patients: a global perspective. Kidney Int. 69, 2057–2063 (2006).

    Article  Google Scholar 

  4. White, S. L. et al. Limited knowledge of kidney disease in a survey of AusDiab study participants. Med. J. Aust. 188, 204–208 (2008).

    PubMed  Google Scholar 

  5. Holman, R. R., Paul, S. K., Bethel, M. A., Matthews, D. R. & Niel, H. A. 10-year follow-up of intensive glucose control in type 2 diabetes. N. Engl. J. Med. 359, 1577–1589 (2008).

    Article  CAS  Google Scholar 

  6. Gaede, P., Lund-Andersen, H., Parving, H. H. & Pederson, O. Effect of a multifactorial intervention on mortality in type 2 diabetes. N. Engl. J. Med. 358, 580–591 (2008).

    Article  CAS  Google Scholar 

  7. Zoungas, S. et al. Combined effects of routine blood pressure lowering and intensive glucose control on macrovascular and microvascular outcomes in patients with type 2 diabetes: new results from the ADVANCE trial. Diabetes Care 32, 2068–2074 (2009).

    Article  CAS  Google Scholar 

  8. Parving, H. H. et al. The effect of irbesartan on the development of diabetic nephropathy in patients with type 2 diabetes. N. Engl. J. Med. 345, 870–878 (2001).

    Article  CAS  Google Scholar 

  9. Lewis, E. J. et al. Renoprotective effect of the angiotensin-receptor antagonist irbesartan in patients with nephropathy due to type 2 diabetes. N. Engl. J. Med. 345, 851–860 (2001).

    Article  CAS  Google Scholar 

  10. Atkins, R., Perico, N., Codreanu, I., Peng, L. & Remuzzi, G. Program for detection and management of chronic kidney disease, hypertension, diabetes and cardiovascular disease in developing countries. International Society of Nephrology [online], (2005).

    Google Scholar 

Download references

Acknowledgements

The authors would like to acknowledge the research contributions of Anne Reutens, Baker IDI Heart and Diabetes Institute, to the manuscript. We would also like to thank the co-chairpersons, William G. Couser and Miguel Riella, and Georgi Abraham, Paul Beerkens, John Feehally, Guillermo Garcia-Garcia, Dan Larson, Philip K. T. Li, Bernardo Rodriguez-Iturbe of the ISN–IFKF World Kidney Day 2010 Steering Committee for their contributions.

Author information

Authors and Affiliations

  1. School of Public Health and Preventative Medicine, Monash University, 89 Commercial Road, Melbourne, 3004, VIC, Australia

    Robert C. Atkins

  2. Baker IDI Heart and Diabetes Institute, 250 Kooyong Road, Caulfield, 3162, VIC, Australia

    Paul Zimmet

Authors
  1. Robert C. Atkins
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Paul Zimmet
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Robert C. Atkins.

Ethics declarations

Competing interests

The authors declare no competing financial interests.

Rights and permissions

Reprints and Permissions

About this article

Cite this article

Atkins, R., Zimmet, P. Diabetic kidney disease: act now or pay later. Nat Rev Nephrol 6, 134–136 (2010). https://doi.org/10.1038/nrneph.2010.10

Download citation

  • Issue Date:

  • DOI: https://doi.org/10.1038/nrneph.2010.10

This article is cited by

Search

Advanced search

Quick links

Nature Briefing

Sign up for the Nature Briefing newsletter — what matters in science, free to your inbox daily.

Get the most important science stories of the day, free in your inbox. Sign up for Nature Briefing